Showing 741-750 of 2373 results for "".
Olfactory Testing in the Diagnosis of Alzheimer's Disease and Other Neuro-Degenerative Disorders
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/PN0809_02-php/30894/Olfactory testing can be a convenient and relatively inexpensive method to gather supporting information for the diagnosis of neuro-degenerative diseases.Sports Concussion and the Clinical Neurologist, Part III
https://practicalneurology.com/diseases-diagnoses/headache-pain/sports-concussion-and-the-clinical-neurologist-part-ii/30784/The third and final installment in a series on sports concussion explores treatment and the role of the neurologist.Stroke Snapshot: Blood Pressure Management After Acute Ischemic Stroke
https://practicalneurology.com/diseases-diagnoses/stroke/stroke-snapshot-blood-pressure-management-after-acute-ischemic-stroke/30115/CLINICAL DECISION MAKING: Managing blood pressure after acute ischemic stroke requires different approaches before and after reperfusion.Patient-Reported Outcome Measures in Neuromuscular Disorders
https://practicalneurology.com/diseases-diagnoses/neuromuscular/patient-reported-outcome-measures-in-neuromuscular-disorders/35531/Information gleaned from patient-reported outcome measures provides valuable insights into the effects of neuromuscular disorders on function and quality of life.- Phase 3 Trial of MSC-NTF Stem Cells for ALS Receives Continued Fundinghttps://practicalneurology.com/news/phase-3-trial-of-msc-ntf-stem-cells-for-als-receives-continued-funding/2469289/The ongoing phase 3 clinical trial of autologous neurotrophic factor-secreting mesenchymal stem cell (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, Paramus, NJ) treatment has received funding through a grant. The grant was awarded by the ALS Association and
- 2024 Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research Presented to Lars Lannfelt, MD, PhDhttps://practicalneurology.com/news/2024-lifetime-achievement-award-in-alzheimers-disease-therapeutic-research-presented-to-lars-lannfelt-md-phd/2470618/Lars Lannfelt, MD, PhD has been recognized as the recipient of the 2024 Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research at the 17th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference. Dr. Lannfelt was selected based on his pioneering work in Alzheim
- Barancik Prize Awarded to Sergio E. Baranzini, PhD at ACTRIMS 2024https://practicalneurology.com/news/barancik-prize-awarded-to-sergio-e-baranzini-phd-at-actrims-2024/2470413/This year, the National Multiple Sclerosis Society has awarded Sergio E. Baranzini, PhD the prestigious Barancik Prize for Innovation in Multiple Sclerosis (MS) Research. Professor Baranzini is a geneticist, neuroimmunologist, and data scientist at the University of California, San Francisco (UCS
- Remembering Ronald DeVere, MD, FAANhttps://practicalneurology.com/news/remembering-ronald-devere-md-faan/2470936/Ronald DeVere, MD, FAAN, Practical Neurology Editorial Advisory Board member and former Editor of the Dementia Insights column, passed away on May 8, 2024, at age 80. Dr. DeVere served as the Director of the Taste & Smell Disorders Clinic and the Alzheimer Disease & Memory Disorder
- Neurotrophic Factor-Secreting Stem Cell Treatment Improves Function in Progressive Multiple Sclerosishttps://practicalneurology.com/news/neurotrophic-factor-secreting-stem-cell-treatment-improves-function-in-progressive-multiple-sclerosis/2470024/As published in Multiple Sclerosis, off-the-shelf growth factor-secreting stem cell (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, New York, NY) treatment of people with progressive multiple sclerosis (MS) im
- Autologous Mesenchymal Stem Cells Expressing Neurotrophic Factors Improved Function and Biomarkers in Progressive Multiple Sclerosishttps://practicalneurology.com/news/autologous-mesenchymal-stem-cells-expressing-neurotrophic-factors-improved-function-and-biomarkers-in-progressive-multiple-sclerosis/2469728/In a trial (NCT03799718) of autologous neurotrophic mesenchymal stem cells (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, New York, NY), 18 individuals with progressive MS were treated, and 16 c